Cargando…

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

BACKGROUND: There are relatively few articles addressing long-term follow-up in women with breast cancer at very young ages. METHODS: We have updated and extended our population-based analysis of breast cancer diagnosed at the age ⩽30 years in North-west England to include an extra 15 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, D G R, Moran, A, Hartley, R, Dawson, J, Bulman, B, Knox, F, Howell, A, Lalloo, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853095/
https://www.ncbi.nlm.nih.gov/pubmed/20234365
http://dx.doi.org/10.1038/sj.bjc.6605606
_version_ 1782180006953222144
author Evans, D G R
Moran, A
Hartley, R
Dawson, J
Bulman, B
Knox, F
Howell, A
Lalloo, F
author_facet Evans, D G R
Moran, A
Hartley, R
Dawson, J
Bulman, B
Knox, F
Howell, A
Lalloo, F
author_sort Evans, D G R
collection PubMed
description BACKGROUND: There are relatively few articles addressing long-term follow-up in women with breast cancer at very young ages. METHODS: We have updated and extended our population-based analysis of breast cancer diagnosed at the age ⩽30 years in North-west England to include an extra 15 patients with mutation testing in BRCA1, BRCA2 and TP53, with 115 of 288 consecutive cases being tested. Kaplan–Meier curves were generated to assess overall survival, contralateral breast cancer and other second primaries. RESULTS: Survival analysis of all 288 patients showed poor overall survival, although this improved from a 15-year survival of only 46% in those diagnosed between 1980 and 1989 to 58% in those diagnosed between 1990 and 1997 (P=0.05). Contralateral breast cancer rates were at a steady rate of 0.6 per 1000, although the rates in mutation carriers were ∼2 per 1000. Altogether, 16 BRCA1, 9 BRCA2 and 6 TP53 mutations have now been found among the 115 cases on whom DNA analysis has been performed. BRCAPRO accurately predicted the number of carriers for BRCA1 and BRCA2 and was sensitive and specific at the 10 and 20% threshold, respectively. However, BRCAPRO did not seem to give any weight to DCIS, which accounted for two BRCA1 carriers and three TP53 carriers and overpredicted mutations at the high end of the spectrum, with only 6 of 11 (54%) with a >90% probability having identifiable BRCA1/2 mutations. INTERPRETATION: Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged ⩽30 years to be tested.
format Text
id pubmed-2853095
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28530952011-03-30 Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status Evans, D G R Moran, A Hartley, R Dawson, J Bulman, B Knox, F Howell, A Lalloo, F Br J Cancer Clinical Study BACKGROUND: There are relatively few articles addressing long-term follow-up in women with breast cancer at very young ages. METHODS: We have updated and extended our population-based analysis of breast cancer diagnosed at the age ⩽30 years in North-west England to include an extra 15 patients with mutation testing in BRCA1, BRCA2 and TP53, with 115 of 288 consecutive cases being tested. Kaplan–Meier curves were generated to assess overall survival, contralateral breast cancer and other second primaries. RESULTS: Survival analysis of all 288 patients showed poor overall survival, although this improved from a 15-year survival of only 46% in those diagnosed between 1980 and 1989 to 58% in those diagnosed between 1990 and 1997 (P=0.05). Contralateral breast cancer rates were at a steady rate of 0.6 per 1000, although the rates in mutation carriers were ∼2 per 1000. Altogether, 16 BRCA1, 9 BRCA2 and 6 TP53 mutations have now been found among the 115 cases on whom DNA analysis has been performed. BRCAPRO accurately predicted the number of carriers for BRCA1 and BRCA2 and was sensitive and specific at the 10 and 20% threshold, respectively. However, BRCAPRO did not seem to give any weight to DCIS, which accounted for two BRCA1 carriers and three TP53 carriers and overpredicted mutations at the high end of the spectrum, with only 6 of 11 (54%) with a >90% probability having identifiable BRCA1/2 mutations. INTERPRETATION: Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged ⩽30 years to be tested. Nature Publishing Group 2010-03-30 2010-03-16 /pmc/articles/PMC2853095/ /pubmed/20234365 http://dx.doi.org/10.1038/sj.bjc.6605606 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Evans, D G R
Moran, A
Hartley, R
Dawson, J
Bulman, B
Knox, F
Howell, A
Lalloo, F
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
title Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
title_full Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
title_fullStr Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
title_full_unstemmed Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
title_short Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
title_sort long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and brca1/brca2/tp53 status
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853095/
https://www.ncbi.nlm.nih.gov/pubmed/20234365
http://dx.doi.org/10.1038/sj.bjc.6605606
work_keys_str_mv AT evansdgr longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status
AT morana longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status
AT hartleyr longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status
AT dawsonj longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status
AT bulmanb longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status
AT knoxf longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status
AT howella longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status
AT lalloof longtermoutcomesofbreastcancerinwomenaged30yearsoryoungerbasedonfamilyhistorypathologyandbrca1brca2tp53status